Search Result for : Generic Drug

The Dollar Business Bureau Moving of manufacturing bases to international markets by some domestic firms and lack of blockbuster drugs going off-patent are some of the reasons for decline in country’s pharma exports, C R Chaudhary, Minister of State for Commerce and Industry informed the Parliament on Wednesday.  The pharmaceutical exports dropped by 0.43% in terms of value and 6.95% in terms of volumes in financial year 2016-17, Chaudhary said in a written response to the Rajya Sabha.  The Minister said some of the reasons for decline in pharma exports include consolidation of buyers in the US into three large groups with significant bargaining power, absence of blockbuster drugs going off-patent and certain Indian companies shifting their manufacturing bases to the US, EU ...

The Dollar Business Bureau Lupin Limited (Lupin), a transnational pharma company, announced on Wednesday that its US-based subsidiary Lupin Pharmaceuticals, Inc (LPI) has got the final approval from FDA for its Armodafinil Tablets, used in treatment of obstructive sleep apnea. “Company’s US subsidiary Lupin Pharmaceuticals, Inc has received final approval for its Armodafinil Tablets 50 mg, 150 mg, 200 mg and 250 mg from the United States Food and Drug Administration (FDA) to market a generic version of Cephalon, Inc’s Nuvigil® Tablets 50 mg, 150 mg, 200 mg and 250 mg,” Lupin said in a release. LPI shall start promoting the products in the US market shortly, it added. The pharma major’s Armodafinil tablets in 250 mg, 200 mg, 150 mg and 50 mg are ...

The Dollar Business Bureau What is said to be the biggest investment by an Indian pharmaceutical major in Europe following the Brexit outcome, Ahmedabad-based Intas has acquired Actavis Generics in the United Kingdom and Ireland for £600 million (around Rs.5100 crore) from Israel's Teva in an all-cash deal. A part of the European Commission's anti-trust divestiture needs emerging from Teva acquisition of Actavis Generics from Ireland-based Allergan unit for $40 billion, the transaction would enable the Indian drug major to tap a high-potential and always-growing UK and Ireland generics markets. This deal will prompt the company to undertake expansion-related initiatives, and it is expected that the company will add one more manufacturing capability to its existing three plants in the UK, ...

The Dollar Business Bureau Committed to enhance India’s market share in Europe, Pharmaceuticals Export Promotion Council (Pharmexcil) is planning to begin its work on preparing a document forecasting the country’s likely CAGR (compounded annual growth rate) in the coming four years. This step comes at a time when pharmaceutical sector is being recognised by government amongst the top sectors for export with high potential. In this context, Pharmexcil has been asked by the government to compile a forecast of possible CAGR in the coming four years, keeping 2015-16 as the base year with a growth rate of 4.5 percent of the country’s pharmaceutical exports to the Europe. To speed up activities, the council has already urged all the stakeholders to provide ...

The Dollar Business Bureau The growth of Indian pharmaceutical exports is likely to come down to 10-12% y-o-y during the next five years, when compared to the growth of 19% in the past ten years, as per CRISIL Research. Due to the decreasing value of off-patent drugs and increasing pressure on prices, the exports of generics have less impact on the growth of the pharma industry, it said. According to CRISIL Research, Indian pharma companies must enhance their investments in new molecules for sustainable growth till 2020 and beyond. The domestic companies shall also prepare a roadmap related to the growth of lower generics. In the last 10 years, process chemistry skills have helped pharma companies to clone off-patent drugs by tweaking ...

 The Dollar Business Bureau Aurobindo Pharma, a Hyderabad-based company, has announced that it has finally received approval to manufacture and market Oxymorphone Hydrochloride and Famotidine tablets from the United States Food and Drug Administration (USFDA). The approved Abbreviated New Drug Application (ANDA) is bio and therapeutic equivalent to listed drug under Reference Listed Drug (RLD). Manufactured by Endo Pharmaceuticals, Inc., Oxymorphone Hydrochloride is a pain relief drug for moderate to acute pain, wherever the prescription of Opioid is appropriate. As approved by ANDA, dosages must be 5mg and 10mg. According to IMS Health, the product has a market size of $55.5 million for a period of 12-months, ending February 2016. While, Famotidine tablets (ANDA approved dosages for this drug is ...

Aadhira Anandh | The Dollar Business Lupin Pharma, the fastest growing generic drug maker has announced the launch of Fyavolv TM Tablets. The tablet is used in the treatment of vasomotor symptoms due to menopause and also for the prevention of postmenopausal osteoporosis. “The drug is an oral contraceptive indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. The launch of our new drug increases accessibility to the product and provides patient with a quality option.” said, Shamsher Gorawara, spokesperson of Lupin Pharmaceuticals. Lupin on Monday announced that, its US subsidiary, Lupin Pharmaceuticals Inc. will launch the tablet in US. The generic drug maker had earlier received the approval from United States Food and Drug ...

Aurobindo Pharma, with its competitively priced generic drugs, eyes on the growing Saudi market of high-quality medicines The Dollar Business Bureau On Monday,Aurabindo Pharmaannounced that it has got final approval from the USFDA to manufacture and market Norethindrone Acetate tablets, which has an estimated market size of $24 million per annum. Indian drug maker Aurobindo Pharma will set up a manufacturing unit at King Abdullah Economic Citys (KAEC) Industrial Valley in Saudi Arabia to produce oral tablets and capsules. The companys investment arm has already leased a site in phase one of the industrial valley to build its manufacturing facility. The deal is part of the joint effort by KAEC and the National Industrial Clusters Development Programme, with pharmaceuticals being one of six major industries ...